ELRIG-Forum 2025: Abstracts

Sebastian Fuchs, Merck KGaA, Darmstadt

At Merck Healthcare, we are working on the acceleration of the Design-Make-Test-Analyze (DMTA) cycle through comprehensive digitalization and automation. We highlight the use of Genedata Screener for automated data analysis, ensuring superior quality control of assay data. By fully automating small-scale assays, we enhance the DMTA process, from test ordering to data upload, significantly minimizing human error and increasing throughput.

Our automation platform comprehensively includes biochemical assays, automating the thawing and preparation of reagents and enzymes. Separately, for cellular processes, we automate cell thawing, mixing, and seeding into 1536-well plates, supporting both high-throughput screening (HTS) and small-scale experiments.

Alessandro Spada, Scitara, USA

"The presentation emphasizes the importance of establishing a robust Digital Core across the enterprise to enable business disruption and reinvention. The foundation of a digital core includes a cloud-first infrastructure, composable integration, and a continuum control plane. We will discuss how this technological shift is critical to achieve:

  • Improved Operations and Cost Reduction: providing real-time visibility into critical business processes leading to cost reduction through improved asset efficiency, worker productivity and reduced technical debt
  • Real-Time Insights: enable stakeholders to predict and simulate anticipated events more accurately and perform advanced analytics for deeper insights and more effective decision-making
  • Flexibility and Agility: help organizations become more flexible and adaptable with changing business conditions, recent innovations, also allowing the rapid integration of emerging technologies"

Kerem Yildrim, Promega, Walldorf

At Promega, we are harnessing the power of AI to enhance efficiency, accuracy, and innovation across our research and development efforts. This presentation will explore our latest AI-driven initiatives, including the integration of ChatGPT for rapid literature analysis and a custom-built GPT model designed to generate structured insights on monoclonal antibody drugs. This specialized tool provides comprehensive summaries on drug targets, manufacturers, and mechanisms of action. Beyond research, we are extending AI applications to customer engagement—leveraging intelligent automation for prospecting and targeted content creation. By streamlining complex data analysis and reporting, our AI solutions reduce manual workload, accelerate decision-making, and optimize workflows throughout the organization. 

 

pfeil zurueck pfeil top